Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Recent Advances in Colorectal Cancer Diagnostics and Treatments
share announcement

Recent Advances in Colorectal Cancer Diagnostics and Treatments

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: closed (10 June 2022) | Viewed by 72302

Special Issue Editors

Prof. Dr. Luis Bujanda

E-Mail Website
Guest Editor
Department of Gastroenterology, Biodonostia Health Research Institute, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco (UPV/EHU), 20014 San Sebastián, Spain
Interests: colorectal cancer; gastrointestinal oncology; prevention; gastric cancer; pancreatic cancer
Prof. Dr. Ajay Goel

grade E-Mail Website
Co-Guest Editor
Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
Interests: cancer epigenetics; ncRNAs; microRNAs; colorectal cancer; oncogenesis; biomarkers
Dr. Ane Etxart

E-Mail
Co-Guest Editor
Department of Surgery, Biodonostia Health Research Institute, Donostia University Hospital, San Sebastián, Spain
Interests: rectum diseases; colorectal surgery; colorectal cancer; gastrointestinal oncology; prevention

Special Issue Information

Dear Colleagues,

It is a pleasure for us to be able to dedicate a Special Issue of the journal Cancers to promote the dissemination of knowledge that helps improve the survival and quality of life of patients with colon cancer. Colorectal cancer is the most common tumor in Western countries when men and women are considered together, and the second in mortality after lung cancer with a survival of 60–70% at 5 years. The objective of all of us who work in and research this disease would be to develop strategies so that in the coming years we can reach 80–90% survival at 5 years. For this, it is necessary to carry out disease prevention policies, develop research that improves biomarkers to detect colon cancer in early stages, extend screening programs, detect people at high risk of developing colon cancer through genetic studies and molecular studies, improve and standardize diagnostic and prognostic techniques, develop methods for detecting recurrences and complete responses (e.g., in rectal cancer), improve treatments in the advanced stages, and develop personalized treatments. For all the above, this Special Issue aims to collect outstanding research in any of these fields that will help us to achieve our objectives.

For this, the journal Cancers will be able to disseminate those advances related to colorectal cancer that help us achieve this goal.

Prof. Dr. Luis Bujanda
Prof. Dr. Ajay Goel
Dr. Ane Etxart
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • colorectal cancer
  • diagnosis
  • treatment
  • screening
  • biomarkers
  • surgery
  • prognosis
  • survival
  • genetics
  • secondary prevention
  • early detection

Published Papers (15 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

12 pages, 811 KiB  
Article
Somatic Mutations in Exon 7 of the TP53 Gene in Index Colorectal Lesions Are Associated with the Early Occurrence of Metachronous Adenoma
by Tereza Hálková, Renata Ptáčková, Anastasiya Semyakina, Štěpán Suchánek, Eva Traboulsi, Ondřej Ngo, Kateřina Hejcmanová, Ondřej Májek, Jan Bureš, Miroslav Zavoral, Marek Minárik and Lucie Benešová
Cancers 2022, 14(12), 2823; https://doi.org/10.3390/cancers14122823 - 7 Jun 2022
Viewed by 1915
Abstract
(1) Background: this prospective study was focused on detailed analysis of the mutation heterogeneity in colorectal lesions removed during baseline (index) colonoscopy to identify patients at high risk of early occurrence of metachronous adenomas. (2) Methods: a total of 120 patients after endoscopic [...] Read more.
(1) Background: this prospective study was focused on detailed analysis of the mutation heterogeneity in colorectal lesions removed during baseline (index) colonoscopy to identify patients at high risk of early occurrence of metachronous adenomas. (2) Methods: a total of 120 patients after endoscopic therapy of advanced colorectal neoplasia size ≥10 mm (index lesion) with subsequent surveillance colonoscopy after 10–18 months were included. In total, 143 index lesions and 84 synchronous lesions in paraffin blocks were divided into up to 30 samples. In each of them, the detection of somatic mutations in 11 hot spot gene loci was performed. Statistical analysis to correlate the mutation profiles and the degree of heterogeneity of the lesions with the risk of metachronous adenoma occurrence was undertaken. (3) Results: mutation in exon 7 of the TP53 gene found in the index lesion significantly correlated with the early occurrence of metachronous adenoma (log-rank test p = 0.003, hazard ratio 2.73, 95% confidence interval 1.14–6.56). We did not find an association between the risk of metachronous adenomas and other markers monitored. (4) Conclusions: the findings of this study could lead to an adjustment of existing recommendations for surveillance colonoscopies in a specific group of patients with mutations in exon 7 of the TP53 gene in an index lesion, where a shortening of surveillance interval may be warranted. Full article
(This article belongs to the Special Issue Recent Advances in Colorectal Cancer Diagnostics and Treatments)
►▼ Show Figures

Figure 1

16 pages, 1787 KiB  
Article
Impact of Age on Multimodality Treatment and Survival in Locally Advanced Rectal Cancer Patients
by Lindsey C. F. De Nes, Thea C. Heil, Rob H. A. Verhoeven, Valery E. P. P. Lemmens, Harm J. Rutten, Johannes H. W. De Wilt and Pauline A. J. Vissers
Cancers 2022, 14(11), 2741; https://doi.org/10.3390/cancers14112741 - 31 May 2022
Cited by 2 | Viewed by 1701
Abstract
Background: Optimal treatment for locally advanced rectal cancer is neoadjuvant (chemo)radiation followed by radical surgery. This is challenging in the aging population because of frequently concomitant comorbidity. We analyzed whether age below and above 70 years is associated with differences in treatment strategy [...] Read more.
Background: Optimal treatment for locally advanced rectal cancer is neoadjuvant (chemo)radiation followed by radical surgery. This is challenging in the aging population because of frequently concomitant comorbidity. We analyzed whether age below and above 70 years is associated with differences in treatment strategy and outcome in this population-based study. Methods: Data between 2008 and 2016 were extracted from the Netherlands Cancer Registry with follow-up until 2021. Differences in therapy, referral and outcome were analyzed using χ2 tests, multivariable logistic regression and relative survival analysis. Results: In total, 6524 locally advanced rectal cancer patients were included. A greater proportion of patients <70 years underwent resection compared to older patients (89% vs. 71%). Patients ≥70 years were more likely treated with neoadjuvant radiotherapy (OR 3.4, 95% CI 2.61–4.52), than with chemoradiation (OR 0.3, 95% CI 0.23–0.37) and less often referred to higher volume hospitals for resection (OR 0.7, 95% CI 0.51–0.87). Five-year relative survival after resection following neoadjuvant therapy was comparable and higher for both patients <70 years and ≥70 years (82% and 77%) than after resection only. Resection only was associated with worse survival in the elderly compared to younger patients (56% vs. 75%). Conclusion: Elderly patients with locally advanced rectal cancer received less intensive treatment and were less often referred to higher volume hospitals for surgery. Relative survival was good and comparable after optimal treatment in both age groups. Effort is necessary to improve guideline adherence, and multimodal strategies should be tailored to age, comorbidity and performance status. Full article
(This article belongs to the Special Issue Recent Advances in Colorectal Cancer Diagnostics and Treatments)
►▼ Show Figures

Figure 1

19 pages, 6941 KiB  
Article
Metformin and ICG-001 Act Synergistically to Abrogate Cancer Stem Cells-Mediated Chemoresistance in Colorectal Cancer by Promoting Apoptosis and Autophagy
by Souvick Roy, Yinghui Zhao, Yate-Ching Yuan and Ajay Goel
Cancers 2022, 14(5), 1281; https://doi.org/10.3390/cancers14051281 - 2 Mar 2022
Cited by 8 | Viewed by 2767
Abstract
Colorectal cancer (CRC) remains the third most frequently diagnosed cancer in the United States. The current treatment regimens for CRC include surgery followed by 5FU-based chemotherapy. Cancer stem-like cells (CSCs) have been implicated in 5FU-mediated chemoresistance, which leads to poor prognosis. In this [...] Read more.
Colorectal cancer (CRC) remains the third most frequently diagnosed cancer in the United States. The current treatment regimens for CRC include surgery followed by 5FU-based chemotherapy. Cancer stem-like cells (CSCs) have been implicated in 5FU-mediated chemoresistance, which leads to poor prognosis. In this study, we used metformin along with ICG-001, a Wnt signaling inhibitor, to abrogate CSC-mediated chemoresistance in CRC. We observed that 5FU-resistant (5FUR) CRC cells exhibited increased expression of CSC markers and enhanced spheroid formation. Genome-wide transcriptomic profiling analysis revealed that Wnt signaling, colorectal cancer metastasis signaling, etc., were enriched in 5FUR CRC cells. Accordingly, selective targeting of Wnt signaling using ICG-001 along with metformin abrogated CSC-mediated chemoresistance by decreasing the expression of CSC markers and promoting autophagy and apoptosis in a synergistic manner. We also observed that metformin and ICG-001 exhibited anti-tumor activity in CRC patient-derived tumor organoids. In conclusion, our study highlights that metformin and ICG-001 act synergistically and can be used as part of a therapeutic strategy to overcome 5FU-mediated therapeutic resistance in CRC. Full article
(This article belongs to the Special Issue Recent Advances in Colorectal Cancer Diagnostics and Treatments)
►▼ Show Figures

Figure 1

12 pages, 787 KiB  
Article
Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
by Alessio Amatu, Gianluca Mauri, Federica Tosi, Katia Bencardino, Erica Bonazzina, Viviana Gori, Lorenzo Ruggieri, Sabrina Arena, Alberto Bardelli, Silvia Marsoni, Salvatore Siena and Andrea Sartore-Bianchi
Cancers 2022, 14(5), 1197; https://doi.org/10.3390/cancers14051197 - 25 Feb 2022
Cited by 9 | Viewed by 2224
Abstract
Background: oxaliplatin with fluoropyrimidine is a “mainstay” regarding the upfront treatment of metastatic colorectal cancer (mCRC). In contrast, the efficacy and safety of oxaliplatin-based regimens in late-care settings have been poorly reported. Methods: we identified a real-world mCRC patient cohort who were re-treated [...] Read more.
Background: oxaliplatin with fluoropyrimidine is a “mainstay” regarding the upfront treatment of metastatic colorectal cancer (mCRC). In contrast, the efficacy and safety of oxaliplatin-based regimens in late-care settings have been poorly reported. Methods: we identified a real-world mCRC patient cohort who were re-treated with oxaliplatin, and in which clinicopathological features were retrospectively analyzed to identify efficacy–predictive determinants (RETROX-CRC study). Results: of 2606 patients, 119 fulfilled the eligibility criteria. Oxaliplatin retreatment response rate (RR) and disease control rate (DCR) were 21.6% (CI 14.4–31.0%), and 57.8% (CI 47.7–67.4). A trend towards better RR and DCR was observed among patients who had first oxaliplatin in an adjuvant setting; a poorer outcome was observed if two or more intervening treatments were delivered. Median progression-free survival (PFS) was 5.1 months (95%CI 4.3–6.1), reducing to 4.0 months (95%CI 3.07–5.13) if oxaliplatin was readministered beyond third-line (HR 2.02; 1.25–3.25; p = 0.004). Safety data were retrieved in 65 patients (54.6%); 18.5% (12/65) and 7.7% (5/65) had G3–4 toxicities. Toxicities led to discontinuation in 34/119 (28.6%). Conclusions: oxaliplatin retreatment produced further RR in around one-fifth of patients and DCR 57.8%. Efficacy decreased in more pre-treated patients and around one-third of patients discontinued treatment due to adverse events. Translational studies improving patient selection are warranted. Full article
(This article belongs to the Special Issue Recent Advances in Colorectal Cancer Diagnostics and Treatments)
►▼ Show Figures

Figure 1

12 pages, 979 KiB  
Article
Diagnostic Performance of a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program According to Ambient Temperature and Humidity
by Gemma Ibáñez-Sanz, Núria Milà, Núria Vives, Carmen Vidal, Gemma Binefa, Judith Rocamora, Carmen Atencia, Víctor Moreno, Rebeca Sanz-Pamplona, Montse Garcia and on behalf of the MSIC-SC Research Group
Cancers 2022, 14(5), 1153; https://doi.org/10.3390/cancers14051153 - 23 Feb 2022
Cited by 1 | Viewed by 1874
Abstract
Exposure of the fecal immunochemical test (FIT) to different ambient temperatures and humidity is unavoidable in population-based screening programs in Southern European countries, and it could lead to a decrease in target colorectal lesions. The objective was to evaluate the effect of ambient [...] Read more.
Exposure of the fecal immunochemical test (FIT) to different ambient temperatures and humidity is unavoidable in population-based screening programs in Southern European countries, and it could lead to a decrease in target colorectal lesions. The objective was to evaluate the effect of ambient temperature and humidity on the FIT sensitivity in a population-based screening program for colorectal cancer (CRC) using an ecological design. The retrospective cohort included individuals aged 50–69 years who participated in CRC screening (Barcelona) from 2010–2015, and were followed until 2017 to identify interval CRCs. The positivity rate, and detection rates for advanced polyps and CRC were compared according to ambient temperature, humidity, and quarters of the year. A positive FIT was defined as the detection of ≥20 μg Hb/g in feces. The monthly ambient temperature and humidity were recorded on the day that the FIT was performed. In total, 92,273 FIT results from 53,860 participants were analyzed. The FIT positivity rate was lower at >24 °C than at ≤24 °C (p = 0.005) but was not affected by humidity. The temperature’s impact on positivity did not lead to a decrease in the FIT detection rate for advanced neoplasia or the interval cancer detection rate in a program where the samples were refrigerated until the analysis and screening invitations were discontinued in July and August. Full article
(This article belongs to the Special Issue Recent Advances in Colorectal Cancer Diagnostics and Treatments)
►▼ Show Figures

Figure 1

13 pages, 870 KiB  
Article
Interplay between Genome, Metabolome and Microbiome in Colorectal Cancer
by Koldo Garcia-Etxebarria, Marc Clos-Garcia, Oiana Telleria, Beatriz Nafría, Cristina Alonso, Marta Iruarrizaga-Lejarreta, Andre Franke, Anais Crespo, Agueda Iglesias, Joaquín Cubiella, Luis Bujanda and Juan Manuel Falcón-Pérez
Cancers 2021, 13(24), 6216; https://doi.org/10.3390/cancers13246216 - 10 Dec 2021
Cited by 15 | Viewed by 4475
Abstract
Background: Colorectal cancer (CRC), a major health concern, is developed depending on environmental, genetic and microbial factors. The microbiome and metabolome have been analyzed to study their role in CRC. However, the interplay of host genetics with those layers in CRC remains unclear. [...] Read more.
Background: Colorectal cancer (CRC), a major health concern, is developed depending on environmental, genetic and microbial factors. The microbiome and metabolome have been analyzed to study their role in CRC. However, the interplay of host genetics with those layers in CRC remains unclear. Methods: 120 individuals were sequenced and association analyses were carried out for adenoma and CRC risk, and for selected components of the microbiome and metabolome. The epistasis between genes located in cholesterol pathways was analyzed; modifiable risk factors were studied using Mendelian randomization; and the three omic layers were used to integrate their data and to build risk prediction models. Results: We detected genetic variants that were associated to components of metabolome or microbiome and adenoma or CRC risk (e.g., in LINC01605, PROKR2 and CCSER1 genes). In addition, we found interactions between genes of cholesterol metabolism, and HDL cholesterol levels affected adenoma (p = 0.0448) and CRC (p = 0.0148) risk. The combination of the three omic layers to build risk prediction models reached high AUC values (>0.91). Conclusions: The use of the three omic layers allowed for the finding of biological mechanisms related to the development of adenoma and CRC, and each layer provided complementary information to build risk prediction models. Full article
(This article belongs to the Special Issue Recent Advances in Colorectal Cancer Diagnostics and Treatments)
►▼ Show Figures

Figure 1

10 pages, 847 KiB  
Article
Faecal Diagnostic Biomarkers for Colorectal Cancer
by Andrea Cruz, Carla M. Carvalho, Alexandra Cunha, Anais Crespo, Águeda Iglesias, Laura García-Nimo, Paulo P. Freitas and Joaquín Cubiella
Cancers 2021, 13(21), 5568; https://doi.org/10.3390/cancers13215568 - 7 Nov 2021
Cited by 7 | Viewed by 2439
Abstract
Background: Colorectal cancer (CRC) is a major cause of cancer-related death worldwide. Cancer progression, including invasion and metastasis, is a major cause of death among CRC patients. Current methods for CRC screening commonly consist of a combination of faecal immunochemical test (FIT) for [...] Read more.
Background: Colorectal cancer (CRC) is a major cause of cancer-related death worldwide. Cancer progression, including invasion and metastasis, is a major cause of death among CRC patients. Current methods for CRC screening commonly consist of a combination of faecal immunochemical test (FIT) for stool occult blood detection and invasive procedures such as colonoscopy. Considering the slow progression of CRC, and that symptoms usually emerge at advanced stages, its early diagnostic can limit cancer’s spread and provide a successful treatment. Biomarkers have a high potential for the diagnosis of CRC in either blood or stool samples. Methods: In this study, we analysed the diagnostic value of six different biomarkers in stool samples of patients with CRC, advanced adenomas, other lesions and healthy individuals. We have also assessed the overall performance of the combination of these biomarkers for CRC detection. Results: The results indicate that haemoglobin (Hb) and M2-pyruvate kinase (M2-PK) levels were increased in CRC patients in comparison to the controls. Conversely, the concentrations of matrix metalloproteinase (MMP)-2, MMP-9, and tumour necrosis factor-alpha (TNF-α) were not significantly different between the tested groups. Conclusion: The combination of FIT-Hb with the M2-PK levels increased the specificity or sensitivity for CRC detection and thus present potential as faecal diagnostic biomarkers for CRC. Full article
(This article belongs to the Special Issue Recent Advances in Colorectal Cancer Diagnostics and Treatments)
►▼ Show Figures

Figure 1

12 pages, 2628 KiB  
Article
Compound Endoscopic Morphological Features for Identifying Non-Pedunculated Lesions ≥20 mm with Intramucosal Neoplasia
by João Pedro da Costa-Seixas, María López-Cerón, Anna Arnau, Òria Rosiñol, Miriam Cuatrecasas, Alberto Herreros-de-Tejada, Ángel Ferrández, Miquel Serra-Burriel, Óscar Nogales, Luisa de Castro, Jorge López-Vicente, Pablo Vega, Marco A. Álvarez-González, Jesús M. González-Santiago, Marta Hernández-Conde, Pilar Diez-Redondo, Liseth Rivero-Sánchez, Antonio Z. Gimeno-García, Aurora Burgos, Francisco Javier García-Alonso, Marco Bustamante-Balén, Eva Martínez-Bauer, Beatriz Peñas, Daniel Rodríguez-Alcalde, Maria Pellisé and Ignasi Puigadd Show full author list remove Hide full author list
Cancers 2021, 13(21), 5302; https://doi.org/10.3390/cancers13215302 - 22 Oct 2021
Cited by 3 | Viewed by 2298
Abstract
Background: The major limitation of piecemeal endoscopic mucosal resection (EMR) is the inaccurate histological assessment of the resected specimen, especially in cases of submucosal invasion. Objective: To classify non-pedunculated lesions ≥20 mm based on endoscopic morphological features, in order to identify those that [...] Read more.
Background: The major limitation of piecemeal endoscopic mucosal resection (EMR) is the inaccurate histological assessment of the resected specimen, especially in cases of submucosal invasion. Objective: To classify non-pedunculated lesions ≥20 mm based on endoscopic morphological features, in order to identify those that present intramucosal neoplasia (includes low-grade neoplasia and high-grade neoplasia) and are suitable for piecemeal EMR. Design: A post-hoc analysis from an observational prospective multicentre study conducted by 58 endoscopists at 17 academic and community hospitals was performed. Unbiased conditional inference trees (CTREE) were fitted to analyse the association between intramucosal neoplasia and the lesions’ endoscopic characteristics. Result: 542 lesions from 517 patients were included in the analysis. Intramucosal neoplasia was present in 484 of 542 (89.3%) lesions. A conditional inference tree including all lesions’ characteristics assessed with white light imaging and narrow-band imaging (NBI) found that ulceration, pseudodepressed type and sessile morphology changed the accuracy for predicting intramucosal neoplasia. In ulcerated lesions, the probability of intramucosal neoplasia was 25% (95%CI: 8.3–52.6%; p < 0.001). In non-ulcerated lesions, its probability in lateral spreading lesions (LST) non-granular (NG) pseudodepressed-type lesions rose to 64.0% (95%CI: 42.6–81.3%; p < 0.001). Sessile morphology also raised the probability of intramucosal neoplasia to 86.3% (95%CI: 80.2–90.7%; p < 0.001). In the remaining 319 (58.9%) non-ulcerated lesions that were of the LST-granular (G) homogeneous type, LST-G nodular-mixed type, and LST-NG flat elevated morphology, the probability of intramucosal neoplasia was 96.2% (95%CI: 93.5–97.8%; p < 0.001). Conclusion: Non-ulcerated LST-G type and LST-NG flat elevated lesions are the most common non-pedunculated lesions ≥20 mm and are associated with a high probability of intramucosal neoplasia. This means that they are good candidates for piecemeal EMR. In the remaining lesions, further diagnostic techniques like magnification or diagnostic +/− therapeutic endoscopic submucosal dissection should be considered. Full article
(This article belongs to the Special Issue Recent Advances in Colorectal Cancer Diagnostics and Treatments)
►▼ Show Figures

Figure 1

12 pages, 1408 KiB  
Article
Validation of Gene Expression-Based Predictive Biomarkers for Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
by Tomoyuki Momma, Hirokazu Okayama, Yasuyuki Kanke, Satoshi Fukai, Hisashi Onozawa, Shotaro Fujita, Wataru Sakamoto, Motonobu Saito, Shinji Ohki and Koji Kono
Cancers 2021, 13(18), 4642; https://doi.org/10.3390/cancers13184642 - 16 Sep 2021
Cited by 6 | Viewed by 2136
Abstract
Background: Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is widely used for patients with locally advanced rectal cancer. However, response to nCRT varies substantially among patients, highlighting the need for predictive biomarkers that can distinguish non-responsive from responsive patients before nCRT. This study aimed [...] Read more.
Background: Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is widely used for patients with locally advanced rectal cancer. However, response to nCRT varies substantially among patients, highlighting the need for predictive biomarkers that can distinguish non-responsive from responsive patients before nCRT. This study aimed to build novel multi-gene assays for predicting nCRT response, and to validate our signature and previously-reported signatures in multiple independent cohorts. Methods: Three microarray datasets of pre-therapeutic biopsies containing a total of 61 non-responders and 53 responders were used as the discovery cohorts to screen for genes that were consistently associated with nCRT response. The predictive values of signatures were tested in a meta-analysis using six independent datasets as the validation cohorts, consisted of a total of 176 non-responders and 99 responders. Results: We identified four genes, including BRCA1, GPR110, TNIK, and WDR4 in the discovery cohorts. Although our 4-gene signature and nine published signatures were evaluated, they were unable to predict nCRT response in the validation cohorts. Conclusions: Although this is one of the largest studies addressing the validity of gene expression-based classifiers using pre-treatment biopsies from patients with rectal cancer, our findings do not support their clinically meaningful values to be predictive of nCRT response. Full article
(This article belongs to the Special Issue Recent Advances in Colorectal Cancer Diagnostics and Treatments)
►▼ Show Figures

Figure 1

16 pages, 34852 KiB  
Article
Impact of Race and Socioeconomics Disparities on Survival in Young-Onset Colorectal Adenocarcinoma—A SEER Registry Analysis
by Mark M. Aloysius, Hemant Goyal, Niraj J. Shah, Kumar Pallav, Nimy John, Mahesh Gajendran, Abhilash Perisetti and Benjamin Tharian
Cancers 2021, 13(13), 3262; https://doi.org/10.3390/cancers13133262 - 29 Jun 2021
Cited by 8 | Viewed by 1968
Abstract
Introduction: We aimed to assess the impact of socio-economic determinants of health (SEDH) on survival disparities within and between the ethnic groups of young-onset (<50 years age) colorectal adenocarcinoma patients. Patients and Methods: Surveillance, epidemiology, and end results (SEER) registry was used to [...] Read more.
Introduction: We aimed to assess the impact of socio-economic determinants of health (SEDH) on survival disparities within and between the ethnic groups of young-onset (<50 years age) colorectal adenocarcinoma patients. Patients and Methods: Surveillance, epidemiology, and end results (SEER) registry was used to identify colorectal adenocarcinoma patients aged between 25–49 years from 2012 and 2016. Survival analysis was performed using the Kaplan–Meir method. Cox proportional hazards model was used to determine the hazard effect of SEDH. American community survey (ACS) data 2012–2016 were used to analyze the impact of high school education, immigration status, poverty, household income, employment, marital status, and insurance type. Results: A total of 17,145 young-onset colorectal adenocarcinoma patients were studied. Hispanic (H) = 2874, Non-Hispanic American Indian/Alaskan Native (NHAIAN) = 164, Non-Hispanic Asian Pacific Islander (NHAPI) = 1676, Non-Hispanic black (NHB) = 2305, Non-Hispanic white (NHW) = 10,126. Overall cancer-specific survival was, at 5 years, 69 m. NHB (65.58 m) and NHAIAN (65.67 m) experienced worse survival compared with NHW (70.11 m), NHAPI (68.7), and H (68.31). High school education conferred improved cancer-specific survival significantly with NHAPI, NHB, and NHW but not with H and NHAIAN. Poverty lowered and high school education improved cancer-specific survival (CSS) in NHB, NHW, and NHAPI. Unemployment was associated with lowered CSS in H and NAPI. Lower income below the median negatively impacted survival among H, NHAPI NHB, and NHW. Recent immigration within the last 12 months lowered CSS survival in NHW. Commercial health insurance compared with government insurance conferred improved CSS in all groups. Conclusions: Survival disparities were found among all races with young-onset colorectal adenocarcinoma. The pattern of SEDH influencing survival was unique to each race. Overall higher income levels, high school education, private insurance, and marital status appeared to be independent factors conferring favorable survival found on multivariate analysis. Full article
(This article belongs to the Special Issue Recent Advances in Colorectal Cancer Diagnostics and Treatments)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

17 pages, 855 KiB  
Review
Copy Number Alterations as Novel Biomarkers and Therapeutic Targets in Colorectal Cancer
by Elaine S. Tan, Todd C. Knepper, Xuefeng Wang, Jennifer B. Permuth, Liang Wang, Jason B. Fleming and Hao Xie
Cancers 2022, 14(9), 2223; https://doi.org/10.3390/cancers14092223 - 29 Apr 2022
Cited by 8 | Viewed by 2937
Abstract
In colorectal cancer, somatic mutations have played an important role as prognostic and predictive biomarkers, with some also functioning as therapeutic targets. Another genetic aberration that has shown significance in colorectal cancer is copy number alterations (CNAs). CNAs occur when a change to [...] Read more.
In colorectal cancer, somatic mutations have played an important role as prognostic and predictive biomarkers, with some also functioning as therapeutic targets. Another genetic aberration that has shown significance in colorectal cancer is copy number alterations (CNAs). CNAs occur when a change to the DNA structure propagates gain/amplification or loss/deletion in sections of DNA, which can often lead to changes in protein expression. Multiple techniques have been developed to detect CNAs, including comparative genomic hybridization with microarray, low pass whole genome sequencing, and digital droplet PCR. In this review, we summarize key findings in the literature regarding the role of CNAs in the pathogenesis of colorectal cancer, from adenoma to carcinoma to distant metastasis, and discuss the roles of CNAs as prognostic and predictive biomarkers in colorectal cancer. Full article
(This article belongs to the Special Issue Recent Advances in Colorectal Cancer Diagnostics and Treatments)
►▼ Show Figures

Figure 1

25 pages, 2559 KiB  
Review
Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies
by Md. Sanower Hossain, Hidayah Karuniawati, Ammar Abdulrahman Jairoun, Zannat Urbi, Der Jiun Ooi, Akbar John, Ya Chee Lim, K. M. Kaderi Kibria, A.K. M. Mohiuddin, Long Chiau Ming, Khang Wen Goh and Muhammad Abdul Hadi
Cancers 2022, 14(7), 1732; https://doi.org/10.3390/cancers14071732 - 29 Mar 2022
Cited by 198 | Viewed by 31261
Abstract
Colorectal cancer (CRC) is the second most deadly cancer. Global incidence and mortality are likely to be increased in the coming decades. Although the deaths associated with CRC are very high in high-income countries, the incidence and fatalities related to CRC are growing [...] Read more.
Colorectal cancer (CRC) is the second most deadly cancer. Global incidence and mortality are likely to be increased in the coming decades. Although the deaths associated with CRC are very high in high-income countries, the incidence and fatalities related to CRC are growing in developing countries too. CRC detected early is entirely curable by surgery and subsequent medications. However, the recurrence rate is high, and cancer drug resistance increases the treatment failure rate. Access to early diagnosis and treatment of CRC for survival is somewhat possible in developed countries. However, these facilities are rarely available in developing countries. Highlighting the current status of CRC, its development, risk factors, and management is crucial in creating public awareness. Therefore, in this review, we have comprehensively discussed the current global epidemiology, drug resistance, challenges, risk factors, and preventive and treatment strategies of CRC. Additionally, there is a brief discussion on the CRC development pathways and recommendations for preventing and treating CRC. Full article
(This article belongs to the Special Issue Recent Advances in Colorectal Cancer Diagnostics and Treatments)
►▼ Show Figures

Figure 1

23 pages, 759 KiB  
Review
Use of Omics Technologies for the Detection of Colorectal Cancer Biomarkers
by Marina Alorda-Clara, Margalida Torrens-Mas, Pere Miquel Morla-Barcelo, Toni Martinez-Bernabe, Jorge Sastre-Serra, Pilar Roca, Daniel Gabriel Pons, Jordi Oliver and Jose Reyes
Cancers 2022, 14(3), 817; https://doi.org/10.3390/cancers14030817 - 6 Feb 2022
Cited by 6 | Viewed by 3339
Abstract
Colorectal cancer (CRC) is one of the most frequently diagnosed cancers with high mortality rates, especially when detected at later stages. Early detection of CRC can substantially raise the 5-year survival rate of patients, and different efforts are being put into developing enhanced [...] Read more.
Colorectal cancer (CRC) is one of the most frequently diagnosed cancers with high mortality rates, especially when detected at later stages. Early detection of CRC can substantially raise the 5-year survival rate of patients, and different efforts are being put into developing enhanced CRC screening programs. Currently, the faecal immunochemical test with a follow-up colonoscopy is being implemented for CRC screening. However, there is still a medical need to describe biomarkers that help with CRC detection and monitor CRC patients. The use of omics techniques holds promise to detect new biomarkers for CRC. In this review, we discuss the use of omics in different types of samples, including breath, urine, stool, blood, bowel lavage fluid, or tumour tissue, and highlight some of the biomarkers that have been recently described with omics data. Finally, we also review the use of extracellular vesicles as an improved and promising instrument for biomarker detection. Full article
(This article belongs to the Special Issue Recent Advances in Colorectal Cancer Diagnostics and Treatments)
►▼ Show Figures

Figure 1

21 pages, 1179 KiB  
Review
Nonmalignant Features Associated with Inherited Colorectal Cancer Syndromes-Clues for Diagnosis
by Diana Haimov, Sari Lieberman, Sergi Castellvi-Bel, Maartje Nielsen and Yael Goldberg
Cancers 2022, 14(3), 628; https://doi.org/10.3390/cancers14030628 - 26 Jan 2022
Cited by 2 | Viewed by 5055
Abstract
Genetic diagnosis of affected individuals and predictive testing of their at-risk relatives, combined with intensive cancer surveillance, has an enormous cancer-preventive potential in these families. A lack of awareness may be part of the reason why the underlying germline cause remains unexplained in [...] Read more.
Genetic diagnosis of affected individuals and predictive testing of their at-risk relatives, combined with intensive cancer surveillance, has an enormous cancer-preventive potential in these families. A lack of awareness may be part of the reason why the underlying germline cause remains unexplained in a large proportion of patients with CRC. Various extracolonic features, mainly dermatologic, ophthalmic, dental, endocrine, vascular, and reproductive manifestations occur in many of the cancer predisposition syndromes associated with CRC and polyposis. Some are mediated via the WNT, TGF-β, or mTOR pathways. However the pathogenesis of most features is still obscure. Here we review the extracolonic features of the main syndromes, the existing information regarding their prevalence, and the pathways involved in their pathogenesis. This knowledge could be useful for care managers from different professional disciplines, and used to raise awareness, enable diagnosis, and assist in the process of genetic testing and interpretation. Full article
(This article belongs to the Special Issue Recent Advances in Colorectal Cancer Diagnostics and Treatments)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

16 pages, 618 KiB  
Systematic Review
Robotic-Assisted vs. Standard Laparoscopic Surgery for Rectal Cancer Resection: A Systematic Review and Meta-Analysis of 19,731 Patients
by Kamil Safiejko, Radoslaw Tarkowski, Maciej Koselak, Marcin Juchimiuk, Aleksander Tarasik, Michal Pruc, Jacek Smereka and Lukasz Szarpak
Cancers 2022, 14(1), 180; https://doi.org/10.3390/cancers14010180 - 30 Dec 2021
Cited by 41 | Viewed by 3481
Abstract
Robotic-assisted surgery is expected to have advantages over standard laparoscopic approach in patients undergoing curative surgery for rectal cancer. PubMed, Cochrane Library, Web of Science, Scopus and Google Scholar were searched from database inception to 10 November 2021, for both RCTs and observational [...] Read more.
Robotic-assisted surgery is expected to have advantages over standard laparoscopic approach in patients undergoing curative surgery for rectal cancer. PubMed, Cochrane Library, Web of Science, Scopus and Google Scholar were searched from database inception to 10 November 2021, for both RCTs and observational studies comparing robotic-assisted versus standard laparoscopic surgery for rectal cancer resection. Where possible, data were pooled using random effects meta-analysis. Forty-Two were considered eligible for the meta-analysis. Survival to hospital discharge or 30-day overall survival rate was 99.6% for RG and 98.8% for LG (OR = 2.10; 95% CI: 1.00 to 4.43; p = 0.05). Time to first flatus in the RG group was 2.5 ± 1.4 days and was statistically significantly shorter than in LG group (2.9 ± 2.0 days; MD = −0.34; 95%CI: −0.65 to 0.03; p = 0.03). In the case of time to a liquid diet, solid diet and bowel movement, the analysis showed no statistically significant differences (p > 0.05). Length of hospital stay in the RG vs. LG group varied and amounted to 8.0 ± 5.3 vs. 9.5 ± 10.0 days (MD = −2.01; 95%CI: −2.90 to −1.11; p < 0.001). Overall, 30-days complications in the RG and LG groups were 27.2% and 19.0% (OR = 1.11; 95%CI: 0.80 to 1.55; p = 0.53), respectively. In summary, robotic-assisted techniques provide several advantages over laparoscopic techniques in reducing operative time, significantly lowering conversion of the procedure to open surgery, shortening the duration of hospital stay, lowering the risk of urinary retention, improving survival to hospital discharge or 30-day overall survival rate. Full article
(This article belongs to the Special Issue Recent Advances in Colorectal Cancer Diagnostics and Treatments)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-15
Back to TopTop